Mesothelin-specific T cell cytotoxicity against triple negative breast cancer is enhanced by 40s ribosomal protein subunit 3-treated self-differentiated dendritic cells
Issued Date
2022-07-01
Resource Type
ISSN
1021335X
eISSN
17912431
Scopus ID
2-s2.0-85131105872
Pubmed ID
35616135
Journal Title
Oncology Reports
Volume
48
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Oncology Reports Vol.48 No.1 (2022)
Suggested Citation
Jirapongwattana N., Thongchot S., Chiraphapphaiboon W., Chieochansin T., Sa-Nguanraksa D., Warnnissorn M., Thuwajit P., Yenchitsomanus P.T., Thuwajit C. Mesothelin-specific T cell cytotoxicity against triple negative breast cancer is enhanced by 40s ribosomal protein subunit 3-treated self-differentiated dendritic cells. Oncology Reports Vol.48 No.1 (2022). doi:10.3892/OR.2022.8338 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/83689
Title
Mesothelin-specific T cell cytotoxicity against triple negative breast cancer is enhanced by 40s ribosomal protein subunit 3-treated self-differentiated dendritic cells
Author's Affiliation
Other Contributor(s)
Abstract
Triple negative breast cancer (TNBC) lacks targeted treatment resulting in poor prognosis. Targeting overex- pressing mesothelin (MSLN) using MSLN-specific T cells is an attractive treatment approach and the aim of the present study. The expression of MSLN in human TNBC paraffin sections was analyzed by immunohistochemistry. Lentiviral vector harbored granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-4 (IL-4) and MSLN cDNAs was constructed to generate self-differentiated myeloid-derived antigen-presenting-cells reactive against tumor expressing MSLN dendritic cell (MSLN-SmartDC) for MSLN-specific T cell activation. The results showed high MSLN in 32.8% of all breast cancer subtypes and 57% in TNBC. High MSLN was significantly associated with TNBC subtype and the absence of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2. MSLN-SmartDC exhib- ited comparable phenotype to DC generated by exogenous cytokine treatment and an addition of 40s ribosomal protein subunit 3 (RPS3), a toll-like receptor 4 ligand, enhanced DC maturation and function by upregulation of CD40, CD80 and CD83 expressions and IL-12p70 secretion. MSLN-specific CD8+CD69+ IFN-γ+ T cells were detected in T cells acti- vated by both MSLN-SmartDC and RPS3-MSLN-SmartDC. MSLN-specific T cells activated by these DCs showed more specific killing capability against naturally expressed MSLN-HCC70 and artificially MSLN-overexpressing MDA-MB-231 compared with parental MDA-MB-231 in both two dimensional (2D)- and 3D-culture systems. In conclusion, the results demonstrated the efficacy of MSLN-SmartDC to promote MSLN-specific T cells response against TNBC and RPS3 can enhance the cytolytic activity of these T cells providing an alternative treatment approach for patients with TNBC.